A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT ID: NCT03602859

Last Updated: 2025-12-31

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 1400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-11
• Study Completion Date: 2029-04-30

Brief Summary

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.

Conditions

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Keywords

FIRST; FIRST trial; Niraparib; Dostarlimab (TSR-042); Ovarian cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Participants receiving SOC+placebo

Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo

Group Type: PLACEBO_COMPARATOR

Standard of care

Intervention Type: DRUG

Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Dostarlimab-Placebo

Intervention Type: DRUG

Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Niraparib-Placebo

Intervention Type: DRUG

Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.

Participants receiving SOC+niraparib

Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo

Group Type: ACTIVE_COMPARATOR

Niraparib

Intervention Type: DRUG

Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

Standard of care

Intervention Type: DRUG

Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Dostarlimab-Placebo

Intervention Type: DRUG

Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Participants receiving SOC+dostarlimab+niraparib

Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab

Group Type: EXPERIMENTAL

Niraparib

Intervention Type: DRUG

Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

Dostarlimab (TSR-042)

Intervention Type: DRUG

Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Standard of care

Intervention Type: DRUG

Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Interventions

Niraparib

Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

Intervention Type: DRUG

Dostarlimab (TSR-042)

Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Intervention Type: DRUG

Standard of care

Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Intervention Type: DRUG

Dostarlimab-Placebo

Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Intervention Type: DRUG

Niraparib-Placebo

Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.

Intervention Type: DRUG

Other Intervention Names

ZEJULA

Eligibility Criteria

Inclusion Criteria

• Participants must be female, >=18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.
• Participants with a histologically confirmed diagnosis of high-grade nonmucinous epithelial ovarian (serous, endometrioid, clear cell, carcinosarcoma, and mixed pathologies), fallopian tube, or peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.
• All participants with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo primary debulking surgery (PDS) (R0 or macroscopic disease), or those for whom neoadjuvant chemotherapy (NACT) is planned.
• Participants with Stage III are eligible if they meet protocol defined criteria.
• Participants must provide a blood sample for circulating tumor deoxyribonucleic acid (ctDNA) homologous recombinant repair (HRR) testing at pre-screening or screening.
• Participant must provide a minimum of 1 formalin-fixed paraffin embedded (FFPE) block slide at pre-screening or screening for PD-L1, homologous recombinant deficiency (HRD) testing.
• Participants of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 3 days prior to receiving the first dose of study treatment.
• Participants must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use highly effective contraception to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.
• Participants must have adequate organ function: Absolute neutrophil count (ANC) >=1500/micro liter (μL;) Platelet count >=100000/μL; Hemoglobin >=9 grams per deciliter (g/dL); Serum creatinine <=1.5 × upper limit of normal (ULN) or calculated creatinine clearance >=60 milliliters per minute (mL/min) using the Cockcroft-Gault equation; total bilirubin <=1.5 × ULN or direct bilirubin <=1.5 × ULN; AST and ALT <=2.5 × ULN unless liver metastases are present, in which case they must be <=5 × ULN.
• Participants must have an ECOG score of 0 or 1.
• Participants must have normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP <=140 millimeters of mercury (mmHg) and/or diastolic BP <=90 mmHg).
• Participants must agree to complete health related quality of life (HRQoL) questionnaires throughout the study.
• Participants must be able to take oral medication.

Exclusion Criteria

• Participant has mucinous, germ cell, transitional cell, or undifferentiated tumor.
• Participant has low-grade or Grade 1 epithelial ovarian cancer.
• Participant has not adequately recovered from prior major surgery.
• Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use, during niraparib treatment and for 30 days after receiving the final dose of study treatment).
• Participant has known active central nervous system metastases, carcinomatous meningitis, or both.
• Participant has clinically significant cardiovascular disease.
• Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, subocclusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
• Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
• Participant has been diagnosed and/or treated with any therapy for invasive cancer <5 years from study enrollment, completed adjuvant chemotherapy and/or targeted therapy (example, trastuzumab) less than 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
• Participants with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, Grade 1 or 2, Stage I endometrial cancer, or non-melanomatous skin cancer are allowed.
• Participant is at increased bleeding risk due to concurrent conditions (example, major injuries or major surgery within the past 28 days prior to start of study treatment and/or history of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
• Participant is immunocompromised.
• Participant has known active hepatitis B (example, hepatitis B surface antigen reactive) or hepatitis C (example, hepatitis C virus ribonucleic acid [qualitative] is detected).
• Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or uncontrolled infection.
• Participant has had investigational therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
• Participant has received a live vaccine within 14 days of planned start of study therapy. Seasonal influenza vaccines that do not contain live viruses are allowed.
• Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, niraparib, bevacizumab, dostarlimab, or their excipients.
• Prior treatment for high-grade nonmucinous epithelial ovarian, fallopian tube, or peritoneal cancer (immunotherapy, anti-cancer therapy, radiation therapy).
• Participant has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (example, thyroid hormone or insulin).
• Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

Sponsor Role: collaborator

Tesaro, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Anchorage, Alaska, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Newport Beach, California, United States

GSK Investigational Site

Farmington, Connecticut, United States

GSK Investigational Site

Hartford, Connecticut, United States

GSK Investigational Site

Gainesville, Florida, United States

GSK Investigational Site

Jacksonville, Florida, United States

GSK Investigational Site

Geneva, Illinois, United States

GSK Investigational Site

Warrenville, Illinois, United States

GSK Investigational Site

Zion, Illinois, United States

GSK Investigational Site

Covington, Louisiana, United States

GSK Investigational Site

New Orleans, Louisiana, United States

GSK Investigational Site

Shreveport, Louisiana, United States

GSK Investigational Site

Scarborough, Maine, United States

GSK Investigational Site

Baltimore, Maryland, United States

GSK Investigational Site

Silver Spring, Maryland, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Springfield, Massachusetts, United States

GSK Investigational Site

Worcester, Massachusetts, United States

GSK Investigational Site

Minneapolis, Minnesota, United States

GSK Investigational Site

Minneapolis, Minnesota, United States

GSK Investigational Site

Billings, Montana, United States

GSK Investigational Site

Neptune City, New Jersey, United States

GSK Investigational Site

Teaneck, New Jersey, United States

GSK Investigational Site

Hawthorne, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Rochester, New York, United States

GSK Investigational Site

Stony Brook, New York, United States

GSK Investigational Site

Syracuse, New York, United States

GSK Investigational Site

Charlotte, North Carolina, United States

GSK Investigational Site

Canton, Ohio, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Oklahoma City, Oklahoma, United States

GSK Investigational Site

Eugene, Oregon, United States

GSK Investigational Site

Portland, Oregon, United States

GSK Investigational Site

Paoli, Pennsylvania, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

GSK Investigational Site

Willow Grove, Pennsylvania, United States

GSK Investigational Site

Wynnewood, Pennsylvania, United States

GSK Investigational Site

Providence, Rhode Island, United States

GSK Investigational Site

Charleston, South Carolina, United States

GSK Investigational Site

Sioux Falls, South Dakota, United States

GSK Investigational Site

Knoxville, Tennessee, United States

GSK Investigational Site

Nashville, Tennessee, United States

GSK Investigational Site

Nashville, Tennessee, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Fort Worth, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

The Woodlands, Texas, United States

GSK Investigational Site

Tyler, Texas, United States

GSK Investigational Site

Ogden, Utah, United States

GSK Investigational Site

Charlottesville, Virginia, United States

GSK Investigational Site

Norfolk, Virginia, United States

GSK Investigational Site

Kennewick, Washington, United States

GSK Investigational Site

Seattle, Washington, United States

GSK Investigational Site

Seattle, Washington, United States

GSK Investigational Site

Minsk, , Belarus

GSK Investigational Site

Brasschaat, , Belgium

GSK Investigational Site

Bruges, , Belgium

GSK Investigational Site

Vancouver, British Columbia, Canada

GSK Investigational Site

London, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Sherbrooke, Quebec, Canada

GSK Investigational Site

Windsor, , Canada

GSK Investigational Site

Prague, , Czechia

GSK Investigational Site

Prague, , Czechia

GSK Investigational Site

Copenhagen, , Denmark

GSK Investigational Site

Herlev, , Denmark

GSK Investigational Site

Roskilde, , Denmark

GSK Investigational Site

Helsinki, , Finland

GSK Investigational Site

Kuopio, , Finland

GSK Investigational Site

Tampere, , Finland

GSK Investigational Site

Turku, , Finland

GSK Investigational Site

Angers, , France

GSK Investigational Site

Avignon, , France

GSK Investigational Site

Besançon, , France

GSK Investigational Site

Bordeaux, , France

GSK Investigational Site

Bron, , France

GSK Investigational Site

Caen, , France

GSK Investigational Site

Cholet, , France

GSK Investigational Site

Clermont-Ferrand, , France

GSK Investigational Site

Dijon, , France

GSK Investigational Site

Grenoble, , France

GSK Investigational Site

Grenoble, , France

GSK Investigational Site

Le Mans, , France

GSK Investigational Site

Lille, , France

GSK Investigational Site

Lyon, , France

GSK Investigational Site

Lyon, , France

GSK Investigational Site

Lyon, , France

GSK Investigational Site

Marseille, , France

GSK Investigational Site

Montpellier, , France

GSK Investigational Site

Montpellier, , France

GSK Investigational Site

Nancy, , France

GSK Investigational Site

Nantes, , France

GSK Investigational Site

Nice, , France

GSK Investigational Site

Nîmes, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Pierre-Bénite, , France

GSK Investigational Site

Plerin-sur-mer, , France

GSK Investigational Site

Poitiers, , France

GSK Investigational Site

Reims, , France

GSK Investigational Site

Rennes, , France

GSK Investigational Site

Saint-Cloud, , France

GSK Investigational Site

Saint-Priest-en-Jarez, , France

GSK Investigational Site

Strasbourg, , France

GSK Investigational Site

Toulouse, , France

GSK Investigational Site

Tours, , France

GSK Investigational Site

Villejuif, , France

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Hamburg, , Germany

GSK Investigational Site

Kiel, , Germany

GSK Investigational Site

Münster, , Germany

GSK Investigational Site

Ravensburg, , Germany

GSK Investigational Site

Wolfsburg, , Germany

GSK Investigational Site

Athens, , Greece

GSK Investigational Site

Athens, , Greece

GSK Investigational Site

Athens, , Greece

GSK Investigational Site

Haidari - Athens, , Greece

GSK Investigational Site

Marousi, , Greece

GSK Investigational Site

Beersheba, , Israel

GSK Investigational Site

Haifa, , Israel

GSK Investigational Site

Haifa, , Israel

GSK Investigational Site

Holon, , Israel

GSK Investigational Site

Petah Tikva, , Israel

GSK Investigational Site

Rehovot, , Israel

GSK Investigational Site

Bologna, , Italy

GSK Investigational Site

Faenza, , Italy

GSK Investigational Site

Lugo RA, , Italy

GSK Investigational Site

Meldola FC, , Italy

GSK Investigational Site

Napoli, , Italy

GSK Investigational Site

Amsterdam, , Netherlands

GSK Investigational Site

Groningen, , Netherlands

GSK Investigational Site

Maastricht, , Netherlands

GSK Investigational Site

Nijmegen, , Netherlands

GSK Investigational Site

Rotterdam, , Netherlands

GSK Investigational Site

Utrecht, , Netherlands

GSK Investigational Site

Kristiansand, , Norway

GSK Investigational Site

Oslo, , Norway

GSK Investigational Site

Tromsø, , Norway

GSK Investigational Site

Olsztyn, , Poland

GSK Investigational Site

Szczecin, , Poland

GSK Investigational Site

Warsaw, , Poland

GSK Investigational Site

Bucharest, , Romania

GSK Investigational Site

Cluj-Napoca, , Romania

GSK Investigational Site

Cluj-Napoca, , Romania

GSK Investigational Site

Constanța, , Romania

GSK Investigational Site

Craiova, , Romania

GSK Investigational Site

Timișoara, , Romania

GSK Investigational Site

Ávila, , Spain

GSK Investigational Site

Badalona, , Spain

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Girona, , Spain

GSK Investigational Site

Jaén, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Santiago de Compostela, , Spain

GSK Investigational Site

Toledo, , Spain

GSK Investigational Site

Valencia, , Spain

GSK Investigational Site

Zaragoza, , Spain

GSK Investigational Site

Chernihiv, , Ukraine

GSK Investigational Site

Kharkiv, , Ukraine

GSK Investigational Site

Lviv, , Ukraine

GSK Investigational Site

Glasgow, , United Kingdom

GSK Investigational Site

Metropolitan Borough of Wirral, , United Kingdom

GSK Investigational Site

Portsmouth, , United Kingdom

GSK Investigational Site

Sutton, , United Kingdom

GSK Investigational Site

Truro, , United Kingdom

Countries

United States; Belarus; Belgium; Canada; Czechia; Denmark; Finland; France; Germany; Greece; Israel; Italy; Netherlands; Norway; Poland; Romania; Spain; Ukraine; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2024-510605-28

Identifier Type: REGISTRY

Identifier Source: secondary_id

213350

Identifier Type: -

Identifier Source: org_study_id